Pharmafile Logo
Pharmafocus logo
Advanced Search

Epidiolex

Showing 11 posts of 11 posts found.

https__cdn

NICE refuses GW Pharma’s cannabis-based Epidyolex for treatment-resistant epilepsy

August 27, 2019
Manufacturing and Production, Sales and Marketing Epidiolex, Epidyolex, GW Pharma, NICE, cannabidiol, cannabis, pharma

UK-based GW Pharma has suffered a setback in its home country after drug watchdog NICE chose not to recommend NHS …

News
https__cdn

GW Pharma’s cannabis-based Epidyolex edges closer to EU approval with positive CHMP opinion in epilepsy

July 26, 2019
Medical Communications, Sales and Marketing EMA, Epidiolex, Europe, GW Pharma, cannabis, epilepsy

UK-based biotech GW Pharmaceuticals has announced that its cannabidiol oral solution Epidyolex has secured recommendation from the European Medicines Agency’s …

News
gwpharma

GW Pharma’s Epidiolex scores in rare childhood onset epilepsy Phase 3 trial

May 7, 2019
Manufacturing and Production, Sales and Marketing CBD, Epidiolex, GW Pharma, cannabidiol, cannabis, epilepsy, tsc

GW Pharma’s Epidiolex has shown positive Phase 3 trial results for the fifth time in a row, after meeting primary …

News
cannabis-2152604_960_720

Australian firm Althea enters UK medicinal cannabis market

February 13, 2019
Research and Development Epidiolex, GW Pharma, Medical marijuana, NHS, UK, cannabis

Melbourne-based medicinal cannabis company Althea has become one of the first companies to enter the UK market after the British …

News
gwpharma

GW Pharma’s Epidiolex becomes first cannabis-based medicine to be made available in United States

November 2, 2018
Medical Communications Epidiolex, GW Pharma, Medical marijuana, cannabidiol, cannabis

GW Pharma’s Epidiolex has become the first plant-derived, cannabis-based medicine to be made available on prescription in all 50 US …

News
gw_pharma

FDA advisory committee sets GW Pharma up for approval

April 20, 2018
Medical Communications, Sales and Marketing Epidiolex, GW Pharma, biotech, drugs, pharma, pharmaceutical

After the FDA advisory committee unanimously recommended GW Pharma’s Epidiolex for approval, the chances of it not receiving the nod …

News
laboratory

GW Pharma releases positive data on cannabidiol-based Phase III trial

September 28, 2016
Research and Development Epidiolex, GW Pharmaceuticals, Marijuana, Medical marijuana, cannabis

GW Pharmaceuticals’ Epidiolex is designed to treat seizures in a rare form of epilepsy called Lennox-Gaustaut Syndrome. GW pharmaceuticals published …

News
gwpharma

GW Pharmaceuticals says Phase III trials for Epidiolex to treat rare epilepsy in children shows positive results

June 27, 2016
Research and Development, Sales and Marketing Epidiolex, GW Pharmaceuticals, NDA, US FDA, drug trial, orphan drug

GW Pharmaceuticals (Nasdaq: GWPH) said late-stage trials for its Epidiolex (cannabidiol or CBD) to treat Lennox-Gastaut syndrome (LGS), a rare …

News
gwpharma

GW Pharma starts Phase III trials for Tuberous Sclerosis Complex drug

April 11, 2016
Research and Development Epidiolex, GW Pharmaceuticals, Tuberous Sclerosis Complex, genetics, rare disease

GW Pharmaceuticals Plc (Nasdaq: GWPH) said it has started late-stage trials for its Epidiolex (cannabidiol or CBD) to treat seizures …

News
gwpharma

GW Pharma shares more than double after positive Phase III trials for epilepsy drug

March 15, 2016
Manufacturing and Production, Research and Development Epidiolex, GW Pharma, US FDA, epilepsy in children, phase III

Shares in UK-based GW Pharmaceuticals (Nasdaq: GWPH) more than doubled on the Nasdaq Monday after the company announced positive results …

News
Sativex image

Late-stage failure for Otsuka and GW cancer pain drug

January 9, 2015
Sales and Marketing Cancer, Epidiolex, GW, MS, NICE, Otsuka, Sativex, cannabidiol, nabiximols

Otsuka and GW Pharmaceutical’s multiple sclerosis drug Sativex has failed to meet the primary endpoint in its first Phase III …

News

Latest content

Sanofi and Teva partner for development of inflammatory bowel disease treatment

October 4, 2023

Eli Lilly to acquire POINT Biopharma

October 4, 2023

Acurx Pharmaceuticals announces positive data from phase 2b trial for C. difficile infection treatment

October 3, 2023

WHO recommends new vaccine for prevention of malaria in children

October 3, 2023

FDA grants marketing authorisation to DNA test for predisposition to certain cancers

October 2, 2023